Jego V - Search Results

1

Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS).

Burton BK, Jego V, Mikl J, Jones SA. Burton BK, et al. Among authors: jego v. J Inherit Metab Dis. 2017 Nov;40(6):867-874. doi: 10.1007/s10545-017-0075-x. Epub 2017 Sep 8. J Inherit Metab Dis. 2017. PMID: 28887757

2

Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS).

Muenzer J, Giugliani R, Scarpa M, Tylki-Szymańska A, Jego V, Beck M. Muenzer J, et al. Among authors: jego v. Orphanet J Rare Dis. 2017 Oct 3;12(1):161. doi: 10.1186/s13023-017-0712-3. Orphanet J Rare Dis. 2017. PMID: 28974237 Free PMC article.

3

Intrafamilial variability in the clinical manifestations of mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS).

Ficicioglu C, Giugliani R, Harmatz P, Mendelsohn NJ, Jego V, Parini R. Ficicioglu C, et al. Among authors: jego v. Am J Med Genet A. 2018 Feb;176(2):301-310. doi: 10.1002/ajmg.a.38551. Epub 2017 Dec 6. Am J Med Genet A. 2018. PMID: 29210515 Free PMC article.

4

Episodic Memory Impairments in Primary Brain Tumor Patients.

Durand T, Berzero G, Bompaire F, Hoffmann S, Léger I, Jego V, Baruteau M, Delgadillo D, Taillia H, Psimaras D, Ricard D. Durand T, et al. Among authors: jego v. Arch Clin Neuropsychol. 2018 Dec 1;33(8):949-955. doi: 10.1093/arclin/acx138. Arch Clin Neuropsychol. 2018. PMID: 29309500

5

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.

Macarulla T, Cervantes A, Tabernero J, Roselló S, Van Cutsem E, Tejpar S, Prenen H, Martinelli E, Troiani T, Laffranchi B, Jego V, von Richter O, Ciardiello F. Macarulla T, et al. Among authors: jego v. Br J Cancer. 2015 Jun 9;112(12):1874-81. doi: 10.1038/bjc.2015.144. Epub 2015 May 19. Br J Cancer. 2015. PMID: 25989270 Free PMC article. Clinical Trial.

6

A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors.

Mita M, Gordon M, Rejeb N, Gianella-Borradori A, Jego V, Mita A, Sarantopoulos J, Sankhala K, Mendelson D. Mita M, et al. Among authors: jego v. Target Oncol. 2014 Sep;9(3):215-24. doi: 10.1007/s11523-013-0288-3. Epub 2013 Jul 6. Target Oncol. 2014. PMID: 23832397 Clinical Trial.

7

A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors.

Raymond E, Alexandre J, Faivre S, Goldwasser F, Besse-Hammer T, Gianella-Borradori A, Jego V, Trandafir L, Rejeb N, Awada A. Raymond E, et al. Among authors: jego v. Invest New Drugs. 2014 Feb;32(1):94-103. doi: 10.1007/s10637-013-9950-y. Epub 2013 Mar 29. Invest New Drugs. 2014. PMID: 23539344 Clinical Trial.

8

[Diagnostic processes in aphasia].

Taillia H, Jego V. Taillia H, et al. Among authors: jego v. Rev Neurol (Paris). 2009 Dec;165 Spec No 4:F256-65. Rev Neurol (Paris). 2009. PMID: 20401996 French. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

8 results

Search Page